Insilico Medicine Raises $60 Million To Develop AI Drug Discovery Platform Pharma.AI
Insilico Medicine, offering an end-to-end stack for AI-powered drug discovery, has raised $60 million through a Series D funding round to continue the fight against disease and illness through ML.
Created on June 6|Last edited on June 6
Comment
Nowadays, AI is the driving force in drug research. With machine learning comes immense power in processing data and developing new potential medicines that could save lives and end diseases.
Insilico Medicine wants to lead the pack in AI powered drug discovery, offering a full end-to-end program for every step of the process, called Pharma.AI. This tech stack spans from the very start to the very end of the process, with initial data analysis, to molecule generation to clinical trials, all driven by machine learning models. They've used this software in collaboration with other companies to develop ground-breaking discoveries.
Who's funding Insilico and where's the money going?
In a Series D funding round, Insilico has raised $60 million thanks to funding efforts by BHR Partners, Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners, and Pavilion Capital. Additionally, Insilico's founder and CEO, Alex Zhavoronkov, invested in the round.
The money will be going towards the continued development of the Pharma.AI platform and global expansion including fully automated AI-driven drug discovery laboratories and biological data factories.
Find out more
Add a comment
Tags: ML News
Iterate on AI agents and models faster. Try Weights & Biases today.